Bayer AG Stock: FDA Fast-Tracks Promising Heart Medication

Bayer AG's stock showed significant gains on Monday, climbing by 1.25% to €23.58 on the XETRA exchange before reaching €23.79 later in the day. This positive movement outperformed the broader Euro Stoxx 50 index, driven by promising news from the pharmaceutical giant's product pipeline. The U.S. Food and Drug Administration (FDA) has granted priority review for Bayer's medication Kerendia (finerenone), potentially shortening the approval timeline from ten to six months. This expedited process could lead to an expanded indication for treating heart failure in patients with a left ventricular ejection fraction of at least 40% as early as the third quarter. The medication is currently approved in over 90 countries for treating chronic kidney disease in patients with type 2 diabetes.

Potential Blockbuster Amid Ongoing Challenges

Anzeige

Sollten Anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei Bayer AG?

Kerendia is widely regarded in medical circles as a potential blockbuster drug with substantial revenue potential. While this development has provided a welcome boost to Bayer's stock, which has been under considerable pressure in recent months, the company continues to face significant headwinds. Despite the positive movement, Bayer's current share price remains well below its 52-week high of €31.03. Analysts maintain an average price target of €24.88 per share and anticipate a modest dividend increase to €0.112 per share for the current fiscal year, compared to €0.110 in the previous period.